Inactive Instrument

Hutchison China MediTech Limited Share Price London S.E.

Equities

KYG4672N1198

Pharmaceuticals

Financials

Sales 2024 * 681M 0 56.81B Sales 2025 * 836M 0 69.69B Capitalization 3.08B 0 257B
Net income 2024 * -109M - -9.09B Net income 2025 * -6M - -500M EV / Sales 2024 * 4.23 x
Net cash position 2024 * 199M 0 16.55B Net cash position 2025 * 306M 0 25.48B EV / Sales 2025 * 3.32 x
P/E ratio 2024 *
-26.7 x
P/E ratio 2025 *
561 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 52.37%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Hutchison China MediTech Limited

Managers TitleAgeSince
Chief Executive Officer 66 01/05/01
Director of Finance/CFO 57 01/08/01
Chief Tech/Sci/R&D Officer 59 01/22/01
Members of the board TitleAgeSince
Chairman 72 01/00/01
Director/Board Member 73 01/17/01
Director/Board Member 70 01/16/01
More insiders
HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.
Calendar
More about the company